Patents by Inventor Joseph E. Wedekind

Joseph E. Wedekind has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Anti-HIV peptides
    Patent number: 11186614
    Abstract: Simple ?-hairpin peptides in linear and cyclic form that specifically bind to HIV-1 Trans-Activation Response element (HIV-1 TAR), as well as compositions and use thereof are described.
    Type: Grant
    Filed: December 20, 2019
    Date of Patent: November 30, 2021
    Assignees: Colorado State University Research Foundation, University of Rochester
    Inventors: Brian R. McNaughton, David W. Crawford, Joseph E. Wedekind, Ivan A. Belashov
  • ANTI-HIV PEPTIDES
    Publication number: 20200115418
    Abstract: Simple ?-hairpin peptides in linear and cyclic form that specifically bind to HIV-1 Trans-Activation Response element (HIV-1 TAR), as well as compositions and use thereof are described.
    Type: Application
    Filed: December 20, 2019
    Publication date: April 16, 2020
    Applicants: COLORADO STATE UNIVERSITY RESEARCH FOUNDATION, University of Rochester
    Inventors: Brian R. McNaughton, David W. Crawford, Joseph E. Wedekind, Ivan A. Belashov
  • Anti-HIV peptides
    Patent number: 10538556
    Abstract: Simple ?-hairpin peptides in linear and cyclic form that specifically bind to HIV-1 Trans-Activation Response element (HIV-1 TAR), as well as compositions and use thereof are described.
    Type: Grant
    Filed: November 7, 2017
    Date of Patent: January 21, 2020
    Assignees: Colorado State University Research Foundation, University of Rochester
    Inventors: Brian R. McNaughton, David W. Crawford, Joseph E. Wedekind, Ivan A. Belashov
  • ANTI-HIV PEPTIDES
    Publication number: 20180127468
    Abstract: The present disclosure provides simple ?-hairpin peptides in linear and cyclic form that specifically bind to HIV-1 Trans-Activation Response element (HIV-1 TAR), as well as compositions and use thereof.
    Type: Application
    Filed: November 7, 2017
    Publication date: May 10, 2018
    Applicants: Colorado State University Research Foundation, University of Rochester
    Inventors: Brian R. McNaughton, David W. Crawford, Joseph E. Wedekind
  • Assay for Screening of Anti-Viral Compounds That Inhibit Specific Interaction Interfaces Between Cullin5 and an ElonginB/ElonginC/ CBF-beta/HIV-1 Vif Complex
    Publication number: 20150268247
    Abstract: The present invention relates to the production of an ElonginB/ElonginC/Vif/CBF? tetramer complex comprising full-length Vif protein. The present invention provides an assay for screening any agent that inhibits the ability of Vif to bind with Cul5. The invention provides an agent identified by the screening methods and methods of treatment using the identified agent. The invention also provides compositions that inhibit Vif-Cul5 binding based upon regions identified in Vif and Cul5 that mediate Vif-Cul5 binding.
    Type: Application
    Filed: October 22, 2013
    Publication date: September 24, 2015
    Inventors: Joseph E. Wedekind, Jason D. Salter, Geoffrey M. Lippa, Ivan A. Belashov
  • Methods and compositions related to the structure and function of APOBEC3G
    Patent number: 8999317
    Abstract: Disclosed are methods and compositions related to the structure and function of APOBEC3G.
    Type: Grant
    Filed: November 1, 2007
    Date of Patent: April 7, 2015
    Assignee: University of Rochester
    Inventors: Harold C. Smith, Joseph E. Wedekind, Ryan Patrick Bennett
  • Solution Assay and High Through-Put Screen to Probe Interaction Between Human Cullin-Ring Ligase Complex and HIV-VIF Protein
    Publication number: 20120271036
    Abstract: The present invention relates to large-scale production of ElonginB, ElonginC, Vif, and Cullin5. The present invention provides an assay for screening any agent that inhibits the ability of Vif to bind with Cul5. The invention provides an agent identified by the screening methods and methods of treatment using the identified agent.
    Type: Application
    Filed: October 29, 2010
    Publication date: October 25, 2012
    Inventors: Harold C. Smith, Jason D. Salter, Joseph E. Wedekind
  • Content dependent inhibitors of cytidine deaminases and uses thereof
    Patent number: 8158770
    Abstract: This invention relates to cytidine deaminase inhibitors (Cytidine deaminase inhibitors) of cytidine deaminases and uses thereof.
    Type: Grant
    Filed: May 6, 2005
    Date of Patent: April 17, 2012
    Assignee: University of Rochester
    Inventors: Joseph E. Wedekind, Harold C. Smith
  • METHODS AND COMPOSITIONS RELATED TO THE STRUCTURE AND FUNCTION OF APOBEC3G
    Publication number: 20100197768
    Abstract: Disclosed are methods and compositions related to the structure and function of APOBEC3G.
    Type: Application
    Filed: November 1, 2007
    Publication date: August 5, 2010
    Inventors: Harold C. Smith, Joseph E. Wedekind, Ryan Patrick Bennett
  • Content dependent inhibitors of cytidine deaminases and uses thereof
    Publication number: 20090099105
    Abstract: This invention relates to cytidine deaminase inhibitors (Cytidine deaminase inhibitors) of cytidine deaminases and uses thereof.
    Type: Application
    Filed: May 6, 2005
    Publication date: April 16, 2009
    Inventors: Joseph E. Wedekind, Harold C. Smith